CD274 and non-small cell lung carcinoma: However, the PD-L1 expression in TCs of biopsy specimens has evolved alongside advances in ICI therapy as a meaningful biomarker for predicting the efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC despite of its limitations.